Table 1.

Absolute counts of severe adverse events, N_SAE, and severe cases of CoViD-19, N_SC19, each for the vaccine (index “_vac”) and the comparison (mostly: placebo) group (index “_com”), as documented by the phase-3 studies (data source); the harm-to-benefit ratio hbr resulting from these counts, and the Time after full vaccination, when the count, until the end of the study, of CoViD-19 cases began; N_t documents the number of subjects in the vaccine group.

Vaccine	Data source	N t	N SAE, vac	N SAE, com	N SC19, vac	N SC19, com	hbr	Time
		[ ]	[ ]	[ ]	[ ]	[ ]	[ ]	[days]
BNT162b2	(6, Figure 3 and Supplementary Tables 3, 5)	21,621	240#	139#	1	5	25#	14
mRNA-1273	(7, Supplementary Tables 8, 10)	15,185	234	202	0	30	1.1	14
Ad26.COV2.S	(8, Table 2 and Supplementary Table 7)	21,895	47⋆	21⋆	14	60	0.6	14
			47⋆	21⋆	5	34	0.9	28
Sputnik V	(9, Table 2)	16,427	45	(3·23=)69†	0	(3·20=)60†	−0.4	14
AZD1222	(11)	5,807	84	91‡	0	2	-	-

^#[Polack ei al. (6), Supplementary Table 3]: In category “serious” instead of “severe”, counts are 126 (vac) and 111 (com), thus, hbr = 3.8 . Note the one and only rating of these counts in (6, p.2608): “Few participants in either group had severe adverse events, serious adverse events, or adverse events leading to withdrawal from the trial”.

^⋆“AEs of interest, …” plus “AEs occurring more frequently …” plus otherwise from “SAE considered related to vaccination”.

^†The comparison group comprises just one third the number of subjects in the vaccine group; the comparison consists of administering the vaccine buffer composition only.

^‡A vaccine against meningococci was administered to compare against AZD1222.